Gyre Therapeutics, Inc. (CBIO) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Gyre Therapeutics, Inc. (CBIO) stock forecast summary
Our AI ranks Gyre Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Gyre Therapeutics, Inc. is a small-cap company with a market capitalization of $1.44B. It ranks number 61 by market capitalization among the 61 Pharmaceutical Preparations issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for CBIO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CBIO included.
Follow CBIO freeCBIO price chart and AI forecast
How CBIO ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Gyre Therapeutics, Inc. (CBIO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | CBIO | Rank |
|---|---|---|
| Market Cap | $1.44B | 61/61 |
| P/B Ratio | 13.34x | 16/43 |
| EPS | $-0.10 | – |
| Book Value/Share | $0.97 | – |
| Revenue/Share | $1.08 | – |
| FCF/Share | $-0.14 | – |
Profitability & Margins
| Metric | CBIO | Rank |
|---|---|---|
| ROIC | -9.8% | 24/42 |
| Gross Margin | 94.3% | 4/30 |
| Operating Margin | -13.9% | 21/34 |
| EBT Margin | -13.4% | 29/41 |
| Tax Rate | -21.4% | – |
Financial Health
| Metric | CBIO | Rank |
|---|---|---|
| Current Ratio | 4.26x | 18/51 |
| Quick Ratio | 3.86x | 6/38 |
| D/E Ratio | 0.32x | 30/43 |
| Financial Leverage | 1.85x | 22/43 |
| Interest Coverage | -19.4x | 28/37 |
| Working Capital | $93M | 48/51 |
Cash Flow
| Metric | CBIO | Rank |
|---|---|---|
| Operating Cash Flow | -$14M | 28/50 |
| Free Cash Flow | -$16M | 23/40 |
| Capital Spending | -$1M | 7/40 |
| OCF Growth YoY | -1663.9% | 27/28 |
| FCF/Sales | -13.1% | 27/35 |
| CapEx/Sales | 1.0% | 26/35 |
Operational Efficiency
| Metric | CBIO | Rank |
|---|---|---|
| Asset Turnover | 0.60x | 11/39 |
| Receivables Turnover | 4.3x | 24/35 |
| Inventory Turnover | 0.6x | 24/28 |
| Fixed Assets Turnover | 4.4x | 22/38 |
| Days Sales Outstanding | 84 days | 12/35 |
| Days Inventory | 613 days | 5/28 |
| Payables Period | 66 days | 21/24 |
| Cash Conversion Cycle | 631 days | 3/22 |
Income Statement
| Metric | CBIO | Rank |
|---|---|---|
| Total Revenue | $120M | 38/40 |
| Operating Income | -$16M | 20/42 |
| R&D Expense | $17M | 49/49 |
| SG&A Expense | $96M | 35/36 |
| Cost of Goods Sold | $7M | 28/28 |
Dividend & Shareholder Information
| Metric | CBIO | Rank |
|---|---|---|
| Shares Outstanding | 112M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $122M | 85.8% of assets |
| Cash & Short-term Investments | $43M | 30.4% of assets |
| Accounts Receivable | $28M | 19.5% of assets |
| Inventory | $11M | 8.0% of assets |
| Total Liabilities | $34M | 24.1% of assets |
| Short-term Debt | $27M | 19.3% of assets |
CBIO quarterly financials and insider trading
Gyre Therapeutics, Inc. (CBIO) industry peers
Companies classified under the same SEC industry code as Gyre Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.85B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $122.98B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $30.70B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B |
| ZLAB Zai Lab Ltd | ▼ | $25.93B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.31B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $19.81B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
| INDV Indivior Pharmaceuticals, Inc. | ▲ | $4.18B |
Where CBIO sits on the market map
Gyre Therapeutics, Inc. (CBIO) stock news
Loading...
Gyre Therapeutics, Inc. (CBIO) stock forecast FAQ
What is the Gyre Therapeutics, Inc. (CBIO) stock forecast?
Our AI ranks Gyre Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Gyre Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for CBIO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Gyre Therapeutics, Inc. forecasts updated?
Gyre Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Gyre Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, CBIO included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Gsk Plc (GSK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.